Relation of Catechol-O-methyltransferase (COMT) Genotype and Response to Cognitive Remediation Schizophrenia

Status unconfirmed · Not applicable

Conditions studied: Chronic Schizophrenia

In brief

This project will explore the relationship between catechol-O-methyltransferase (COMT) Val158/108Met genotype and response to a 12-week computerized neurocognitive rehabilitation (CRT) given to chronic schizophrenic patients.

Key facts

Study ID

NCT00664274

Run by

Manhattan Psychiatric Center

People needed

142

Starts

2007-04-01

Expected to finish

2016-10-01

Last updated by the study team

2015-04-17

Who can join

Age: 18 and older, up to 55. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Participation in the active arm of the neurocognitive remediation program
• Age 18 - 55
• Inpatients
• DSM-IV diagnosis of schizophrenia (all subtypes) with illness duration >5 years
• Auditory and visual acuity adequate to complete cognitive tests
• Stable dose of oral atypical antipsychotic for at least 4 weeks
• Total PANSS score > 60
• RBANS total score ≤ 80
• MMSE score of greater than or equal to 24
• Good physical health determined by physical examination, laboratory tests
• Capacity and willingness to give written informed consent

You may not qualify if…

• Inability to read or speak English
• Documented disease of the central nervous system
• History of intellectual impairment pre-dating onset of symptoms of psychosis (e.g. mental retardation)
• Clinically significant or unstable cardiovascular, renal, hepatic, gastrointestinal, pulmonary or hematologic conditions
• HIV +
• Patients diagnosed with substance dependence
• Currently participating in another experimental study, except for the parent study.

Where it is running

• Manhattan Psychiatric Center — Wards Island, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.